Hypertension has been associated with increased casefatality rates among individuals who subsequently suffer from acute coronary events. It is unknown whether inflammation modifies this relationship. This population-based study explored the effects of inflammation and hypertension on incidence of coronary event, and on the fatality of the future events. Blood pressure (BP) and five inflammation-sensitive plasma proteins (ISPs, fibrinogen, orosomucoid, a1-antitrypsin, haptoglobin and ceruloplasmin) were determined in 6071 healthy men. During the mean follow-up of 19 years, 679 men had a first coronary event (non-fatal myocardial infarction or death from coronary heart disease). Of them, 197 (29%) were fatal cases (death during the first day). As expected, hypertension was associated with increased incidence of coronary events and increased proportion of fatal cases. At all levels of BP, high ISPs (X2 ISPs in top quartile) significantly added to the incidence of events. Men with high ISPs had the highest case-fatality rates. The difference in case-fatality rate between men with and without high ISPs was, however, significant only in men with normal BP (o130/85 mm Hg) (33 vs 19%, Po0.05), and not in men with moderate or severe hypertension (X160/100 mm Hg) (40 vs 35%, P ¼ 0.32). High ISPs add to the incidence of coronary events at all levels of BP. Hypertension and inflammation are both independently associated with increased case-fatality in subjects who later have an acute coronary event. The influence of ISPs on the case-fatality rate seems to be most important in men with normal BP.
Introduction
The relationship between hypertension and coronary heart disease (CHD) has been documented in many prospective studies. 1 Hypertension is also associated with increased case-fatality after acute coronary events. [2] [3] [4] [5] Approximately 30-40% of these patients die during the first day, most of them outside hospital, 6 and this proportion is even greater in hypertensive subjects. [1] [2] [3] [4] [5] Hypertension has been associated with increased case-fatality even in population-based studies where the risk factors were assessed many years before the onset of clinical CHD. [1] [2] [3] [4] [5] The factors and circumstances that contribute to the less favourable prognosis in hypertensive patients have not received much scientific attention.
Blood pressure (BP) generally correlates weakly and positively with plasma levels of various inflammatory markers, including fibrinogen, ceruloplasmin, a1-antitrypsin, orosomucoid, haptoglobin, C-reactive protein (CRP) and interleukin-6. [7] [8] [9] [10] Raised concentrations of inflammatory markers have been associated with increased incidences of cardiovascular diseases. [10] [11] [12] [13] [14] [15] [16] [17] Furthermore, men who have been exposed to elevated levels of inflammatory proteins many years earlier have higher fatality in future coronary events, with a higher proportion of CHD deaths and less non-fatal myocardial infarction (MI). 15, 17 It is unknown whether low-grade inflammation further increases the proportion of fatal events in men with hypertension.
Fibrinogen, ceruloplasmin, a1-antitrypsin, orosomucoid and haptoglobin are acute-phase plasma proteins that increase in response to infection or inflammation. 18 These proteins are used in clinical practice in order to assess type and degree of inflammation. Previous studies from the Malmö Preventive study have shown that moderately increased levels of these proteins are strongly associated with incidence of MI, 14,17 stroke 10,14 and other cardiovascular diseases. 19, 20 The purpose of this study was to explore whether raised levels of these proteins modified the relationships between hypertension and case-fatality rates.
Methods
Complete birth cohorts from the city of Malmö , Sweden, were invited to a cardiovascular screening examination. 21 A total of 22 444 men participated (attendance rate: 71%). The determination of five plasma proteins was part of the programme for 6193 men, randomly selected from birth cohorts examined between 1974 and 1982. After exclusion of men with a history of MI, stroke or cancer, and men with missing data on BP, 6071 men remained with a mean age of 46.873.7 years (range: 28-61). The health service authority of Malmö approved and funded the screening programme. All participants gave informed consent.
Baseline examinations
Blood pressure (mm Hg) was measured twice in the right arm after 10 min rest. The average of two measurements was used. A sphygmomanometer and a rubber cuff of appropriate size were used. Blood pressure was categorized into four categories, that is, normal BP (o130/85 mm Hg), high-normal BP (130-139 and/or 85-89 mm Hg), mild hypertension (140-159 and/or 90-99 mm Hg), moderate or severe hypertension (X160 and/or 100 mm Hg). 22 Use of antihypertensive medication was assessed in a questionnaire.
Subjects were categorized into smokers and nonsmokers. Smokers were categorized into consumers of less than 10 cigarettes per day, 10-19 cigarettes and daily consumption of 20 cigarettes or more.
Blood samples were taken after an overnight fast. Serum cholesterol and triglyceride concentrations were analysed with standard methods at the laboratory of the hospital. Diabetes was defined as fasting whole blood glucose X6.1 mmol/l, 2 h glucose X10.0 mmol/l (oral glucose load: 30 g/m 2 body surface area) or self-reported diabetes.
Physical activity was assessed in a questionnaire. Men who reported that they mostly were sedentary in spare time were considered to be physically inactive.
Subjects who confirmed a doctor's diagnosis of angina pectoris or who used nitrates were considered to have angina pectoris.
Inflammation-sensitive plasma proteins Electroimmuno assay was used to analyse the plasma levels of five inflammation-sensitive plasma protein (ISPs). 23 Blood samples were drawn in the morning after an overnight fast and the non-frozen samples were analysed consecutively. The coefficient of variation was below 5%. 23 The detection limits were 20 mg/l for ceruloplasmin, 50 mg/l for a1-antitrypsin and 350 mg/l for orosomucoid, haptoglobin and fibrinogen.
We have previously shown that all ISPs are associated with incidence of cardiovascular disease with largely the same relative risks (RRs) for all individual ISPs.
14 Moreover, the cardiovascular risk increases with the number of ISPs in the top quartile. 7, 10, 14, 17, 19, 20 In accordance with the previous studies, the sample was categorized into men with 0-1 and 2-5 ISPs in the top quartile (low vs high ISPs). The top quartiles were as follows: fibrinogen 44.0 g/l, orosomucoid 40.93 g/l, a1-antitrypsin 41.42 g/l, haptoglobin 41.76 g/l and ceruloplasmin 40.36 g/l.
Follow-up, definition of end points At the baseline examination, none of the men had a history of MI according to the self-report, the Malmö Myocardial Infarction Register or the Swedish Hospital Discharge register. [24] [25] [26] All men were followed from the baseline examination until the first coronary event, death or 31 December, 1998.
A coronary event (n ¼ 679) was defined as non-fatal MI (ICD-9 code 410) or death from CHD (ICD 410-414) in subjects with no prior clinical history of MI.
Fatal CHD (first day) was defined as death during the day of the coronary event, in-or outside hospital (n ¼ 197).
Of the 197 cases that died the first day, cause of death was based on autopsy in 150 (75%) cases. Of the remaining 47, cause of death was based on examinations in-hospital before death for 31 cases, on findings from examinations outside hospital before death for eight cases and on other sources for eight cases.
Statistics
Analysis of variance and Pearson's w 2 -square was used to study differences in risk factors between categories of BP. A general linear model was used to adjust the relationships for confounding factors. Cox proportional hazards regressions was used to calculate adjusted RRs of coronary events. Logistic regression was used to analyse the proportion of fatal cases out of all coronary events. Possible interactions between BP and ISPs were assessed by adding an interaction term. Antihypertensive medication, diabetes, smoking, angina and physical inactivity were modelled as categorical variables. All other covariates were modelled as continuous variables.
Results
Relationship between inflammation-sensitive plasma proteins and blood pressure Table 1 presents baseline characteristics in relation to BP. The relationships between ISPs and BP are presented in Table 2 . After adjustments for con-founding factors, all ISPs were significantly associated with BP.
Incidence of coronary events in relation to blood pressure and inflammation-sensitive plasma proteins All five ISPs were significantly associated with incidence of coronary events. The age-adjusted RRs for the different inflammatory proteins (Q4 vs Q1-3) ranged between 1.58 (1.3-1.9) for ceruloplasmin and 1.82 (1.6-2.1) for fibrinogen. After full adjustments for BP and other confounding factors, the adjusted RRs ranged between 1.21 (1.03-1.44, haptoglobin) and 1.42 (CI: 1.2-1.7, a1-antitrypsin).
For men with 0, 1, 2 and 3 or more ISPs in the top quartile, the multivariate-adjusted RRs were 1.00, 1.14 (0.92-1.4), 1.48 (1.2-1.9) and 1.71 (1.4-2.1), respectively (trend, Po0.001).
Incidence of coronary events in relation to BP and ISPs is presented in Table 3 and Figure 1 . At all levels of BP, incidence of coronary event was significantly higher in men with X2 ISPs in the top quartile.
Case-fatality rates in relation to blood pressure and inflammation-sensitive plasma proteins Hypertension and high ISPs were both significantly associated with increased case-fatality. After adjustments for BP and other confounding factors (see footnote in Table 3 ), the odds ratio (OR) for death during the first day was 1.00 (reference), 1.04 (0.6-1.7), 1.30 (0.76-2.2) and 1.78 (1.10-2.9), respectively, for men with 0, 1, 2 and X3 ISPs in the top quartile. The corresponding ORs for the BP categories were 1.00 (reference), 0.98 (0. 5-1.8), 1.08 (0.7-1.8) and 1.82 (1.02-3.2) , respectively, for men with normal BP, high-normal BP, mild hypertension and moderate or severe hypertension. Table 3 shows how elevated ISPs add to the casefatality rates in the categories of BP. Within all BP categories, the proportion of fatal cases was higher in those with high ISPs than in those with low ISPs. The difference in case-fatality rate between men with low and high ISPs was greater in men with normal BP (19 vs 33%, adjusted OR: 1.00 vs 2.3, Po0.05) than in men with moderate or severe hypertension (35 vs 40%, adjusted OR: 2.4 vs 3.4, P ¼ 0.33). There was however no significant interaction between BP and ISPs on the risk of fatal outcome.
Additional analyses
The results were recalculated after classifying all subjects with antihypertensive treatment as moder- ate or severe hypertension (X160/100 mm Hg). The results were essentially unchanged. The results were also virtually unchanged when men with antihypertensive treatment were excluded from the analysis.
Discussion
Hypertension is associated with increased plasma levels of inflammatory proteins. Elevated ISPs significantly added to the incidence of coronary events, at all levels of BP. At all levels of BP, the case-fatality rates were higher in men with high ISPs. However, the difference in case-fatality rate between men with and without low grade inflammation was greater in men with normal BP (19 vs 33%, Po0.05) than in men with moderate or severe hypertension (35 vs 40%, P ¼ 0.33). Several factors could contribute to the relationship between hypertension and increased fatality rates. Hypertension is associated with left ventricular hypertrophy and the development of ventricular arrhythmia. 27, 28 Hypertension is also associated with coronary atherosclerosis and impaired endotheliumdependent vasodilatation, 29 which could increase the risk of myocardial ischaemia and electrical instability. Activation of the renin-angiotensinaldosterone system and the sympathetic system in hypertensive patients could also increase the risk of ventricular arrhythmia. 27 The reasons for the increased case-fatality rate in men who have had low-grade inflammation are less clear. Size and location of the infarction and ventricular arrhythmia are important prognostic markers among those who survive the acute phase. Whether the relation between inflammation and fatal outcomes is mediated through these factors is, for obvious reasons, impossible to study in population-based settings that include outof-hospital deaths. However, it has been reported that raised CRP levels are associated with atrial fibrillation 30 and that inflammation could facilitate electrical remodelling in men with arrhythmia. 31, 32 C-reactive protein has been associated with increased heart rate and reduced heart rate variability, two putative markers of sympatho-vagal imbalance. 33 The relationship between inflammation and case-fatality rate was significant only in subjects with normal BP. Although speculatively, this could suggest that hypertension and inflammation are related to case-fatality through the same mechanisms, and that one of them is sufficient to increase the risk. It is also possible that a larger sample would produce significant differences at all levels of BP.
The inclusion of out-of-hospital deaths is of vital importance for representative studies of case-fatality rates after acute coronary events. The validity of the diagnosis is another important factor. A validation study from the Swedish Hospital Discharge Register showed that the diagnosis 'MI' is incorrect only in 5% of the cases. 25 The autopsy rates were very high during the study period, particularly for those who died outside hospital, which is a major strength of the study. All men in this study were without a history of MI at the screening examination, according to self-report and local and national registers. All cases were thus first clinically apparent events. Many MIs are unrecognized, 34 however, and we do not know if some men had had a silent MI.
The laboratory tests were limited to those available in clinical practice at the time of the examination, which is a limitation of the study. Many inflammatory markers, for example, CRP, tumour necrosis factor-a and interleukin-6 were unavailable in clinical practice at that time. However, the relationships with incidence of coronary events are largely in accordance with the results from a study of women, in which CRP was used. 13 Change of exposure during follow-up is a potential cause of bias in prospective studies. Initiation of BP treatment in men with high BP would, if anything, reduce the differences between BP groups. Incidence of hypertension in men with initially normal BP would have the same effect. Elevated ISPs have been associated with development of high BP 7 and future weight gain. 35 Hence, it is possible that BP increased mostly in men with high ISPs and that the increased cardiovascular risk among men with high ISPs is partly mediated through development of hypertension after the baseline examination. However, the effect of such relationship is probably rather small and there was no evidence of any interaction between these variables. Furthermore, we do not know if the concentrations of the inflammatory proteins changed. A substantial proportion of the variability of acute-phase proteins seems, however, to be genetically determined. 36 A random variation of the ISP concentrations over the follow-up period would, if anything, reduce the associations with cardiovascular disease.
Hypertension is associated with elevated ISPs. Presence of high ISPs increase the incidence of coronary events at all levels of BP. Hypertension and inflammation are both independently associated with increased case-fatality after future coronary events. However, the relationship between high ISPs and case-fatality seems to be most pronounced in men with normal BP.
Conflict of interests
None.
